Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naproxen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 11/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 11/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CDC42 | P60953 | 1/20 | 1.00 |
| ▸ | RAC1 | P63000 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.65 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naproxen SCHEMBL29360045 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29350675 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL28834409 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL616149 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL42434 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29359528 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29350704 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL3046 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL10029028 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL30346195 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088150-B2 | Device for disc shunt implantation and peri-shunt injection | ALEEVA MEDICAL INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-20110183946-A1 | Complexes Comprising alpha2-Adrenergic Receptor Agonists and Methods of Providing Neuroprotection or Treating or Inhibiting Progression of Glaucoma | WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.) | 2011-07-28 | — | — | US | claimed |
| CN-1236758-C | Slow-releasing injection contg. hydrocastor oil/medicine (for treatment) solid dispersion microparticle | WANG YUWAN (CN) | 2006-01-18 | — | — | CN | claimed |
| CN-1583174-A | Long-term injection containing ethylcellulose and fatty acid ester | WANG YUWAN (CN) | 2005-02-23 | — | — | CN | claimed |
| CN-1533764-A | Slow release injection preparation containing non sterol anti inflammation medicine | 王玉万 | 2004-10-06 | — | — | CN | claimed |
| CN-1490009-A | Sustained release injection containing medicine against coccindian | 王玉万 | 2004-04-21 | — | — | CN | claimed |
| CN-1461639-A | Slow-releasing injection contg. hydrocastor oil/medicine (for treatment) solid dispersion microparticle | WANG YUWAN (CN) | 2003-12-17 | — | — | CN | claimed |
| CN-1444925-A | Long acting injection containing ethyl cellulose for animal | WANG YUWAN (CN) | 2003-10-01 | — | — | CN | claimed |
| CN-114746753-A | Correlating AKR1C3 enzyme expression level through prostaglandin content and screening administration application | 深圳艾欣达伟医药科技有限公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| CN-107072765-A | Method and apparatus for ocular disorders after treatment | 科尼尔赛德生物医学公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-2892518-A2 | NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE | Pharnext (FR) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014037416-A2 | NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE | PHARNEXT (FR) | 2014-03-13 | — | — | WO | disclosed |
| EP-0805684-A2 | METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDS AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022780-A1 | METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDS AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-08-01 | — | — | WO | disclosed |
| WO-1996019431-A1 | RESOLUTION OF IBUPROFEN USING A N-ALKYL-D-GLUCAMINE | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | disclosed |
| US-4803079-A | ORAL ADMINISTRATION; ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1989-02-07 | — | — | US | disclosed |
| US-4571333-A | IN HYDROXYPROPYLMETHYL CELLULOSE MATRIX | SYNTEX (U.S.A.) INC. (US) | 1986-02-18 | — | — | US | disclosed |
| US-4518608-A | INDOMETHALIN WITH HYDROPHILIC COMPOUND FOR PARENTERAL ADMINISTRATION | MEDIMPEX GYOGYSZERKUELKERESKEDELMI VAALLALAT (HU) | 1985-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183946-A1 | Complexes Comprising alpha2-Adrenergic Receptor Agonists and Methods of Providing Neuroprotection or Treating or Inhibiting Progression of Glaucoma | ADRB2, ADRA2A, ADRA2C | PTGS2 97/4885PTGS1 311/4885AKR1C3 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.